Some Cancer Drugs in Clinical Trials Don't Work by Hitting Their Targets (1 of 2) (VIDEO)

American Association for the Advancement of Science (AAAS)

Caption

Cells treated with the preclinical drug candidate OTS964 slowly progressing through cell division. This material relates to a paper that appeared in the Sep. 11, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by A. Lin at Cold Spring Harbor Laboratory in Cold Spring Harbor, NY; and colleagues was titled, "Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials."

Credit

[Credit: A. Lin <em>et al., Science Translational Medicine</em> (2019)]

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <em>Science</em> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.